RhumbLine Advisers’s Matinas BioPharma MTNB Stock Holding History

RhumbLine Advisers’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-872	Closed	-$33K	–	2920
2018 Q1	$33K	Buy	872 +14	+2%	+$740	﹤0.01%	2806
2017 Q4	$50K	Sell	858 -175	-17%	-$11.3K	﹤0.01%	2815
2017 Q3	$68K	Buy	1,033 +17	+2%	+$1.14K	﹤0.01%	2885
2017 Q2	$86K	Buy	+1,016	New	+$136K	﹤0.01%	2899

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

RhumbLine Advisers's MTNB Position: Q2 2018 in Review

RhumbLine Advisers sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 872 shares — an estimated $33K sold.

RhumbLine Advisers first reported a position in MTNB in Q2 2017 and held it in 4 quarters. The position peaked at $86K in Q2 2017. 39 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

RhumbLine Advisers reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
RhumbLine Advisers sold 872 Matinas BioPharma shares in Q2 2018, an estimated $33K.
RhumbLine Advisers first reported a position in Matinas BioPharma in Q2 2017 and held it in 4 quarters.
RhumbLine Advisers's Matinas BioPharma position peaked at $86K in Q2 2017.
39 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on RhumbLine Advisers's 13F filing for Q2 2018, filed 6 Aug 2018.